How to buy Sesen Bio (SESN) stock

Sesen Bio, Inc is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 27 staff and has a trailing 12-month revenue of around 0.00.

Sesen Bio stock price (NASDAQ: SESN)

Use our graph to track the performance of SESN stocks over time.

Sesen Bio shares at a glance

• Key figures

Information last updated 2021-07-24.

Latest market close	$3.35
52-week range	$0.91 - $4.80
50-day moving average	$4.13
200-day moving average	$2.92
Wall St. target price	$7.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.05

Buy Sesen Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sesen Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sesen Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sesen Bio price performance over time

Historical closes compared with the close of $3.35 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	-19.66%
3 months (2021-04-26)	13.18%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Sesen Bio financials

Revenue TTM	$15.5 million
Gross profit TTM	$-17,955,000
Return on assets TTM	-11.6%
Return on equity TTM	-861.97%
Profit margin	0%
Book value	$0.05
Market capitalisation	$668.9 million

TTM: trailing 12 months

Shorting Sesen Bio shares

There are currently 16.7 million Sesen Bio shares held short by investors – that's known as Sesen Bio's "short interest". This figure is 79.1% up from 9.3 million last month.

There are a few different ways that this level of interest in shorting Sesen Bio shares can be evaluated.

Sesen Bio's "short interest ratio" (SIR)

Sesen Bio's "short interest ratio" (SIR) is the quantity of Sesen Bio shares currently shorted divided by the average quantity of Sesen Bio shares traded daily (recently around 8.6 million). Sesen Bio's SIR currently stands at 1.95. In other words for every 100,000 Sesen Bio shares traded daily on the market, roughly 1950 shares are currently held short.

However Sesen Bio's short interest can also be evaluated against the total number of Sesen Bio shares, or, against the total number of tradable Sesen Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sesen Bio's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Sesen Bio shares in existence, roughly 100 shares are currently held short) or 0.0963% of the tradable shares (for every 100,000 tradable Sesen Bio shares, roughly 96 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sesen Bio.

Find out more about how you can short Sesen Bio stock.

Sesen Bio share dividends

We're not expecting Sesen Bio to pay a dividend over the next 12 months.

Sesen Bio share price volatility

Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0.91 up to $4.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 0.8814. This would suggest that Sesen Bio's shares are less volatile than average (for this exchange).

Sesen Bio overview

Sesen Bio, Inc. , a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc.

Frequently asked questions

What percentage of Sesen Bio is owned by insiders or institutions?
Currently 0.007% of Sesen Bio shares are held by insiders and 24.746% by institutions. How many people work for Sesen Bio?
Latest data suggests 27 work at Sesen Bio. When does the fiscal year end for Sesen Bio?
Sesen Bio's fiscal year ends in December. Where is Sesen Bio based?
Sesen Bio's address is: 245 First Street, Cambridge, MA, United States, 02142 What is Sesen Bio's ISIN number?
Sesen Bio's international securities identification number is: US8177631053 What is Sesen Bio's CUSIP number?
Sesen Bio's Committee on Uniform Securities Identification Procedures number is: 286221106